Current Report Filing (8-k)
08 November 2017 - 8:04AM
Edgar (US Regulatory)
U.S. SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported):
November 6, 2017
iBio, Inc.
(Exact name of registrant as specified in
its charter)
Delaware
(State or jurisdiction of incorporation
or organization)
001-35023
(Commission File Number)
26-2797813
(I.R.S. Employer Identification Number)
600 Madison Avenue, Suite 1601,
New York, NY 10022-1737
(Address of principal executive offices
(Zip Code)
Registrant's telephone number: (302) 355-0650
N/A
(Former name or former address, if changed
since last report)
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction
A.2. below):
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).
¨
If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act.
¨
Emerging growth company
iBio, Inc., a Delaware corporation (“iBio”),
announced on November 6, 2017, that it initiated litigation against Fraunhofer-Gesellschaft (Fraunhofer) by filing a complaint
in the Court of Chancery of the State of Delaware to remedy the consequences of Fraunhofer’s fraud and theft of iBio’s
technology and intellectual property. This complaint follows iBio’s pending litigation filed in March 2015 against Fraunhofer
USA, Inc., the U.S. unit of Fraunhofer, as reported in Item 3 of iBio’s Form 10-K for the year ended June 30, 2017.
|
Item 9.01
|
Financial Statements and Exhibits.
|
*Filed herewith.
Signatures
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf
by the undersigned hereunto duly authorized.
|
|
IBIO INC.
|
|
|
|
|
|
|
|
|
|
|
Date: November 7, 2017
|
By:
|
/s/ Robert
B. Kay
|
|
|
|
|
Robert B. Kay
|
|
|
|
|
Executive Chairman and CEO
|
iBio (AMEX:IBIO)
Historical Stock Chart
From Apr 2024 to May 2024
iBio (AMEX:IBIO)
Historical Stock Chart
From May 2023 to May 2024